Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
- Lung transplant recipients and immunocompetent adults who are willing to receive a respiratory syncytial virus (RSV) vaccine will be recruited at the study hospital.
- Participants will receive a single intramuscular dose of the RSV vaccine (RSVPreF3, Arexvy®)
- Participants will be contacted by telephone on Day 7 and at the Day 30 follow-up visit after vaccination to assess adverse events.
- Immunogenicity will be evaluated before vaccination and at 1 month and 12 months after vaccination, and safety will be monitored throughout the study period.
- Changes in immune responses from pre-vaccination levels will be compared between lung transplant recipients and immunocompetent adults.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Chan Mi Lee, M.D., PhD.
- Telefonnummer: 82-2-2072-1473
- E-Mail: heaven229@naver.com
Studieren Sie die Kontaktsicherung
- Name: Young Hoon Hwang, M.D.
- Telefonnummer: 82-2-2072-2228
- E-Mail: hyh0307@gmail.com
Studienorte
-
-
Jongno-Gu
-
Seoul, Jongno-Gu, Südkorea, 03080
- Rekrutierung
- Seoul National University Hospital
-
Kontakt:
- Nam Joong Kim, M.D., PhD.
- Telefonnummer: 82-2-2072-0835
- E-Mail: njkmd@snu.ac.kr
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria (for lung transplant recipient) :
- Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
- Recipients of a lung transplant who are receiving immunosuppressive therapy to prevent allograft rejection.
Inclusion Criteria (for control) :
- Adults aged 60 years or older who voluntarily provide written informed consent to participate in the study.
- Individuals who do not have medical conditions associated with immunocompromise (e.g., malignancy, bone marrow transplantation, solid organ transplantation, HIV infection, or dialysis) and have not received ongoing chemotherapy, radiation therapy, immunosuppressive therapy, or immunomodulatory therapy within 6 months before vaccination.
Exclusion Criteria:
Participants will be excluded if they meet any of the following criteria
- Previous receipt of any RSV vaccine.
- RSV infection diagnosed within the past 12 months.
- History of a severe allergic reaction to any component of the RSV vaccine.
- Moderate or severe acute illness at the time of screening.
- Pregnancy, planned pregnancy, or breastfeeding.
- Any underlying medical condition for which intramuscular injection is contraindicated.
- Any other condition that, in the investigator's judgment, may make the participant unsuitable for evaluation of immune responses.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Lung transplant recipient
Lung transplant recipients aged ≥19 years receiving immunosuppressive therapy (n=60) |
One dose of RSVPreF3 (Arexvy®) vaccine |
|
Aktiver Komparator: Control
Immunocompetent adults aged ≥60 years (n=20) |
One dose of RSVPreF3 (Arexvy®) vaccine |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
Zeitfenster: 1 month after vaccination
|
Geometric mean fold rise (GMFR) in RSV-A neutralizing antibody titers from pre-vaccination to 1 month after vaccination, compared between lung transplant recipients and immunocompetent adults. |
1 month after vaccination
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
Zeitfenster: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-A neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Zeitfenster: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-B neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Zeitfenster: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-A neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
Zeitfenster: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-B neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Zeitfenster: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in RSVPreF3-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Zeitfenster: Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in pan-RSV-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Zeitfenster: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSVPreF3-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
Zeitfenster: 1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in pan-RSV-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (serologic response rate)
Zeitfenster: 1 month, 12 months after vaccination
|
Proportion of participants with a ≥4-fold increase in antibody levels from pre-vaccination levels |
1 month, 12 months after vaccination
|
|
Cell mediated immunity
Zeitfenster: 1 month, 12 months after vaccination
|
Frequency of RSV F-specific CD4+ and CD8+ T cells following stimulation with RSV F peptide pools, measured by flow cytometry. |
1 month, 12 months after vaccination
|
|
Safety (solicited adverse events)
Zeitfenster: 7 days, 30 days after vaccination
|
Proportion of participants experiencing solicited local and systemic adverse events following vaccination. |
7 days, 30 days after vaccination
|
|
Safety (unsolicited adverse events, serious adverse events)
Zeitfenster: Up to 12 months after vaccination
|
Proportion of participants experiencing unsolicited adverse events or serious adverse events following vaccination. |
Up to 12 months after vaccination
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Nam Joong Kim, M.D., PhD., Seoul National University Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Walsh EE, Perez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Ramet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B; RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
- Tan CS, Anjan S, Ariza-Heredia EJ, Magana F, Minniear TD, Kaur D, Falck-Ytter Y, Baden L. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients. Clin Infect Dis. 2026 Aug 24;82(Suppl 3):i123-i128. doi: 10.1093/cid/ciag117.
- Mayer EF, Falsey AR, Wolfe CR, Herc E, Burns F, Kabbani D, Kumar D, Mannan A, She F, Lan L, McGrath S, Kapoor A, Priddy F. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345. Clin Infect Dis. 2026 May 20;82(5):e1112-e1121. doi: 10.1093/cid/ciag108.
- Levy L, Yahav D, Benzimra M, Bezalel Y, Hoffman T, Shirin N, Sinai T, Jurkowicz M, Deri O, Matalon N, Saute M, Lustig Y, Nachum E, Peled M, Nemet I, Mandelboim M. Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains. Vaccines (Basel). 2025 Apr 11;13(4):398. doi: 10.3390/vaccines13040398.
- Ferguson M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Grosskopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrom V; RSV OA=ADJ-018 Study Group. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age. Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364.
- Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M. Use of Respiratory Syncytial Virus Vaccines in Adults Aged >/=60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1.
- Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, Havers FP. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. doi: 10.15585/mmwr.mm7229a4.
- Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrom V; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
- Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020 Sep 14;222(8):1298-1310. doi: 10.1093/infdis/jiaa361.
- Na SH, Jo HJ, Park JJ, Seo Y, Lee J, Bae J, Lee M, Lee CM, Kang CK, Choe PG, Park WB, Kim NJ. Comparison of clinical characteristics and outcomes in hospitalized adult patients infected with respiratory syncytial virus and influenza virus. Infect Dis (Lond). 2025 Feb;57(2):159-166. doi: 10.1080/23744235.2024.2402914. Epub 2024 Sep 16.
- de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, Permpalung N, Kerstjens H, Alffenaar JW, Verschuuren E. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. Clin Infect Dis. 2022 Jul 6;74(12):2252-2260. doi: 10.1093/cid/ciab969.
- Havers FP, Whitaker M, Melgar M, Chatwani B, Chai SJ, Alden NB, Meek J, Openo KP, Ryan PA, Kim S, Lynfield R, Shaw YP, Barney G, Tesini BL, Sutton M, Talbot HK, Olsen KP, Patton ME; RSV-NET Surveillance Team. Characteristics and Outcomes Among Adults Aged >/=60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus - RSV-NET, 12 States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 6;72(40):1075-1082. doi: 10.15585/mmwr.mm7240a1.
- Tin Tin Htar M, Yerramalla MS, Moisi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020 Feb 13;148:e48. doi: 10.1017/S0950268820000400.
- Solidoro P, Curtoni A, Minuto S, Shbaklo N, De Rosa FG, Bondi A, Sidoti F, Patrucco F, Zanotto E, Corcione S, Boffini M, Marro M, Costa C, Rinaldo RF. Impact of RSV Infection in Transplant and Immunocompromised Population: Incidence and Co-Infections: Retrospective Analysis of a Single Centre. J Clin Med. 2025 Jul 7;14(13):4803. doi: 10.3390/jcm14134803.
- Mahan LD, Points A, Mohanka MR, Bollineni S, Joerns J, Kaza V, La Hoz RM, Gao A, Zhang S, Torres F, Banga A. Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transpl Infect Dis. 2021 Aug;23(4):e13661. doi: 10.1111/tid.13661. Epub 2021 Jun 22.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2608-187-1775
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
We are not planning to share IPDs publically, but de-identified individual participant data for all outcome measures could be shared with other researchers under their request.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .